MPCCC 2019 Cancer Forum Dinner
Tuesday 3 September 2019
Huntingdale Golf Course
Windsor Avenue, Oakleigh South
|
|
|
|
MPCCC Precision Oncology Seminar Genome Profiling of Cancers of Unknown Primary
Presented by guest speaker, Dr Richard Tothill, Rare Disease Oncogenomics laboratory, Centre for Cancer Research, University of Melbourne.
Friday 30 August, 12.30-1.30pm
Frankston Hospital
REGISTER NOW »
|
|
|
|
MPCCC to pilot real-time PROMS and PREMS
Two complementary pilot projects will serve as vital foundation work for the implementation of Patient-Reported Outcome Measures (PROMs) and Patient-Reported Experience Measures (PREMs) across MPCCC hospitals, and inform future improvements to patient care and quality of life. Continue reading »
|
|
|
|
Breast cancer research gains welcome boost
Professor Roger Daly, Head of the Monash Biomedicine Discovery Institute (BDI) Cancer Program, has received a major grant from the National Breast Cancer Foundation (NBCF) and Love Your Sister Foundation (LYSF). Continue reading »
|
|
|
|
Training to meet demand in the growing cell therapy industry
Cell therapy is a burgeoning area of medical science with the potential to reverse the downward spiral of life-threatening diseases. Its application ranges from helping extremely sick babies, to acute stroke patients, to cancer patients. However, there is a major gap in this rapidly growing industry: qualified staff who can undertake the cell manufacturing needed as part of the therapy. Continue reading »
|
|
|
|
Technology based on Monash research licensed by PureTech Health to Boehringer Ingelheim
Collaboration will use technology licensed to PureTech Health to develop Boehringer Ingelheim’s novel immuno-oncology product candidates. The Monash Institute of Pharmaceutical Sciences (“MIPS”) today announced that technology it recently licensed to PureTech Health plc (LSE: PRTC) (“PureTech Health”), has become the subject of a research collaboration with Boehringer Ingelheim. Continue reading »
|
|
|
|
Breast cancer drug may hold key to tackling most deadly type of melanoma
An Australian-led international team of researchers has discovered that a drug traditionally used to treat a type of breast cancer may hold the key to treating an aggressive and deadly form of melanoma. Continue reading »
|
|
|
Menopause specialists warn against dangers of bioidentical hormone therapy
Menopause experts have issued a warning to women using bioidentical hormone therapy, claiming the treatment is highly ineffective, costly, and could put women at risk of cancer. Sold as a menopause treatment, bioidentical hormone therapy is often marketed as a "natural" alternative to hormone replacement therapy (HRT) and is a combination of oestrogen, progestogen and other hormones. Continue reading »
|
|
|
New era of insights with release of survival by stage at diagnosis data for top five cancers
Cancer Australia has published an analysis of national data on survival by stage at diagnosis for the top five high incidence cancers – female breast, colorectal, lung, melanoma, and prostate. Continue reading »
|
|
|
World’s melanoma capital needs more dermatologist
AUSTRALIA’S Olympic swimming gold medallist, Cate Campbell, recently posted a photo on her Instagram account of a large scar on her arm where a stage I melanoma had just been removed. This follows a celebrity trend of posting content regarding their respective skin cancer experiences; including Hugh Jackman, who has had five basal cell carcinomas removed from his face and AFL Hawthorn club captain, Jarryd Roughead, who has publicly shared his battle with metastatic melanoma. Continue reading »
|
|
|
The Aussies denied insurance cover because of their genes
Insurance companies have been accused of illegally denying insurance to people carrying cancer-causing genes even when they eliminate their disease risk by removing body parts. Continue reading »
|
|
|
Training to meet demand in growing cell therapy industry
Cell therapy is a burgeoning area of medical science with the potential to reverse the downward spiral of life-threatening diseases. Its application ranges from helping extremely sick babies, to acute stroke patients, to cancer patients. However, there is a major gap in this rapidly growing industry: qualified staff who can undertake the cell manufacturing needed as part of the therapy. Continue reading »
|
|
|
In May, Cancer Australia published up to date statistics on 31 tumour types in Australia, including data on Aboriginal and Torres Strait Islander people. More information »
TaskExchange is an online, free, collaborative platform connecting people who need help or advice on health evidence projects with people who have the time and expertise to help. You can find help for any aspect of your project; for example screening papers, extracting data, or consumer review. 80% of people find the help they need on TaskExchange! So the question is “What are you waiting for!?” Sign up today, feel free to send us an email at taskexchange@cochrane.org, or come and visit us at Cochrane Australia! More information »
NHMRC's Direct Research Costs (DRC) guidelines have been revised to align with NHMRC’s new grant program and provide guidance on expenditure of NHMRC funds. The updated guidelines apply to all new expenditure commitments from NHMRC grants and funding requests in NHMRC applications. More information »
|
|
|
Victorian Cancer Plan 2020-2024 consultation for cancer clinicians and researchers complete online survey or submit your interest to attend one of the consultations sessions. Find out more »
MRFF International Clinical Trial Collaborations (ICTC) – Applications close on 15 August 2019 with minimum data due on 31 July 2019. Find out more »
MRFF Biomedical Translation Bridge Program – Expressions of Interest close 16 August 2019 at 5:00PM. Find out more »
NHMRC Partnership Projects PRC2 – Applications close on 14 August 2019 with minimum data due 31 July 2019. Find out more »
MRFF Genomics Health Futures Mission Pathogen Genomics - Applications close 12 September 2019 5:00 pm AEST. Find out more »
Victorian Cancer Agency 2019 Funding Round includes Early-career Research Fellowships; Mid-career Research Fellowships; Clinical Research Fellowships and Cancer Prevention and Screening Research Grants. Applications close 5pm on 25 September 2019. Find out more »
|
|
NOS2 and COX2 as major drivers of poor outcome in
ER- breast cancer with Dr David Wink
Date: Tuesday 30 July
Where: Monash University, Clayton Campus
Information and Registration
Monash Bioinformatics Informal Seminar
Date: Wednesday 31 July
Where: Alfred Centre, Melbourne
Information and Registration
Women in Leadership
Date: 15 - 16 August; 16 -17 October
Where: Monash Medical Centre (Clayton)/Monash University, Public Health and Preventive Medicine (St Kilda Rd)
Information and Registration (August)
Information and Registration (October)
2019 Victorian Cancer Bioinformatics Symposium
Date: Friday 16 August
Where: Victorian Comprehensive Cancer Centre, Melbourne
Information and Registration
MPCCC Precision Oncology Seminar with Dr Richard Tothill
Date: Friday 30 August
Where: Frankston Hospital
Information and Registration
Cancer Survivorship for Primary Practitioners Workshop
Date: Saturday 7 September
Where: Victorian Comprehensive Cancer Centre, Parkville
Information and Registration
VCCC Research Conference 2019
Date: 16-17 September
Where: Sofitel Melbourne
Information and Registration
VCCC Melanoma Biomarker Symposium
Date: Wednesday 18 September
Where: Sofitel Melbourne
Information and Registration
|
Australian Clinical Trials Alliance (ACTA) International Clinical Trials Conference
Date: 2-5 October
Where: ICC Sydney
Information and Registration
2019 Conference of the Australasian Genomic Technologies Association
Date: 7-9 October
Where: The Pullman, Albert Park Lake
Information and Registration
5th Victorian Psycho-oncology Conference
Date: Friday 8 November
Where: Victorian Comprehensive Cancer Centre Melbourne
Information and Registration
APIC2 - 2nd Asia Pacific Conference on Integrated Care
Date: 11-13 November
Where: Melbourne
Information and Registration
8th Annual NHMRC Symposium on Research Translation
Date: 19-20 November
Where: The Pullman, Albert Park Lake
Information and Registration
COSA’s 46th Annual Scientific Meeting
Date: 12-14 November
Where: Adelaide Convention Centre
Information and Registration
The International Conference on Genome Informatics
Date: 9-11 December
Where: Charles Perkins Centre, University of Sydney
Information and Registration
|
|
The increasing use of shave biopsy for diagnosing invasive melanoma in Australia. Read article »
Activin A-induced cachectic wasting is attenuated by systemic delivery of its cognate propeptide in male mice. Read article »
Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary. Read article »
Shared roles for Scl and Lyl1 in murine platelet production and function. Read article »
FDG-PET follow up of Non-Small Cell Lung Cancer: Not dead yet. Read article »
Genetic discrimination by Australian insurance companies: a survey of consumer experiences. Read article »
Physical activity participation and the risk of chronic diseases among South Asian adults: a systematic review and meta-analysis. Read article »
Hi-Plex2: a simple and robust approach to targeted sequencing-based genetic screening. Read article »
An allied health rehabilitation program for patients following surgery for abdomino-pelvic cancer: a feasibility and pilot clinical study. Read article »
|
|
|
|
|
Monash Partners Comprehensive Cancer Consortium (MPCCC) is a strategic alliance of health service and research organisations working in partnership to improve cancer outcomes through integrated, collaborative and innovative research, service improvement and clinical care programs. MPCCC is the Cancer and Blood Diseases Theme of Monash and is aligned with the Southern Melbourne Integrated Cancer Service (SMICS). Our partner organisations include Monash University, Hudson Institute of Medical Research, Alfred Health, Monash Health, Peninsula Health, Cabrini Health and Eastern Health.
|
|
|
